The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Real-world treatment duration of ruxolitinib and transfusion use in patients with myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the encouraging findings from a real-world retrospective analysis of ruxolitinib treatment duration and transfusion use in patients with myelofibrosis (MF). Dr Bose notes that the median treatment duration of 3.1 years is consistent with the COMFORT trials and that early initiation of ruxolitinib is associated with superior outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
